5,400 Shares in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Acquired by AXS Investments LLC

Key Points

• AXS Investments LLC has made a significant investment of $670,000 in Jazz Pharmaceuticals PLC, acquiring approximately 5,400 shares of the company.
• Ownership of Jazz Pharmaceuticals is heavily concentrated among institutional investors, with 89.14% of the company's stock held by these entities.
• Recent earnings reports for Jazz Pharmaceuticals showed a significant loss of ($8.25) earnings per share, missing analyst expectations while revenue remained steady at $1.05 billion.

AXS Investments LLC purchased a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 5,400 shares of the specialty pharmaceutical company's stock, valued at approximately $670,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Hurley Capital LLC bought a new position in shares of Jazz Pharmaceuticals during the 1st quarter worth $25,000. Quadrant Capital Group LLC raised its position in shares of Jazz Pharmaceuticals by 97.1% in the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock worth $25,000 after acquiring an additional 101 shares in the last quarter. Elequin Capital LP raised its position in shares of Jazz Pharmaceuticals by 677.8% in the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock worth $26,000 after acquiring an additional 183 shares in the last quarter. Parallel Advisors LLC raised its position in shares of Jazz Pharmaceuticals by 85.6% in the 1st quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company's stock worth $32,000 after acquiring an additional 119 shares in the last quarter. Finally, Spire Wealth Management raised its position in shares of Jazz Pharmaceuticals by 137.6% in the 1st quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company's stock worth $35,000 after acquiring an additional 161 shares in the last quarter. Institutional investors own 89.14% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently commented on JAZZ. Needham & Company LLC reissued a "buy" rating and issued a $202.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, June 11th. Royal Bank Of Canada reduced their price target on Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Piper Sandler reissued an "overweight" rating and issued a $147.00 price target (down from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Robert W. Baird reduced their price target on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Finally, Wall Street Zen lowered Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 15th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $181.43.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, Director Seamus Mulligan bought 1,621 shares of the firm's stock in a transaction on Monday, May 12th. The shares were acquired at an average cost of $103.00 per share, with a total value of $166,963.00. Following the purchase, the director directly owned 101,621 shares of the company's stock, valued at $10,466,963. This trade represents a 1.62% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $107.63, for a total value of $107,630.00. Following the completion of the sale, the chief executive officer owned 436,973 shares in the company, valued at $47,031,403.99. This represents a 0.23% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.30% of the company's stock.

Jazz Pharmaceuticals Stock Performance

JAZZ stock traded down $0.78 during trading on Friday, hitting $111.30. 893,673 shares of the company traded hands, compared to its average volume of 771,387. The stock's 50-day simple moving average is $111.27 and its 200 day simple moving average is $117.53. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 2.97. The company has a market cap of $6.73 billion, a PE ratio of -16.54, a P/E/G ratio of 6.52 and a beta of 0.34. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The company had revenue of $1.05 billion for the quarter, compared to analysts' expectations of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The firm's revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $5.30 earnings per share. On average, equities analysts expect that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.